Thomas Scattolin

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 8

Top Venues

Organic letters

Chemistry (Weinheim an der Bergstrasse, Germany)

Mirati Therapeutics

RWTH Aachen University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Mirati Therapeutics Apr 13 2020

United States

Research Scientist :: Process Research & Developement

H Lee Moffitt Cancer Center and Research Center Inc Nov 01 2018 - Mar 31 2020

United States

Postdoctoral Fellow :: Drug Discovery Department

Syngenta Crop Protection AG Standort Stein Nov 01 2011 - Nov 30 2013

Switzerland

Research Associate :: Early Process Chemistry

Education History

RWTH Aachen University Apr 01 2014 - Oct 01 2018

Germany

PHD :: Institut of Organic Chemistry

Université Montpellier Faculté des Sciences de Montpellier Sep 01 2009 - Sep 01 2011

France

MSC :: Organic Chemistry

Publications

Cheng-Yi Chen, Zhichao Lu, Thomas Scattolin, Chengsheng Chen, Yonghong Gan, Mark McLaughlin
Synthesis of Adagrasib (MRTX849), a Covalent KRAS G12C Inhibitor Drug for the Treatment of Cancer. Organic letters 25 (6) (2023)
Cheng-Yi Chen, Zhichao Lu, Thomas Scattolin, Chengsheng Chen, Yonghong Gan, Mark McLaughlin
Synthesis of Adagrasib (MRTX849), a Covalent KRAS G12C Inhibitor Drug for the Treatment of Cancer. Organic letters 25 (6) (2023)
Cheng-Yi Chen, Zhichao Lu, Thomas Scattolin, Chengsheng Chen, Yonghong Gan, Mark McLaughlin
Synthesis of Adagrasib (MRTX849), a Covalent KRAS G12C Inhibitor Drug for the Treatment of Cancer. Organic letters 25 (6) (2023)
Cheng-Yi Chen, Zhichao Lu, Thomas Scattolin, Chengsheng Chen, Yonghong Gan, Mark McLaughlin
Synthesis of Adagrasib (MRTX849), a Covalent KRAS G12C Inhibitor Drug for the Treatment of Cancer. Organic letters 25 (6) (2023)
Cheng-Yi Chen, Zhichao Lu, Thomas Scattolin, Chengsheng Chen, Yonghong Gan, Mark McLaughlin
Synthesis of Adagrasib (MRTX849), a Covalent KRAS G12C Inhibitor Drug for the Treatment of Cancer. Organic letters (2023)
Cheng-Yi Chen, Zhichao Lu, Thomas Scattolin, Chengsheng Chen, Yonghong Gan, Mark McLaughlin
Synthesis of Adagrasib (MRTX849), a Covalent KRAS G12C Inhibitor Drug for the Treatment of Cancer. Organic letters 25 (6) (2023)
Thomas Scattolin, Tawfik Gharbaoui, Cheng-Yi Chen
A Nucleophilic Deprotection of Carbamate Mediated by 2-Mercaptoethanol. Organic letters 24 (20) (2022)
Thomas Scattolin, Maoping Pu, Franziska Schoenebeck
Investigation of (Me4 N)SCF3 as a Stable, Solid and Safe Reservoir for S=CF2 as a Surrogate for Thiophosgene. Chemistry (Weinheim an der Bergstrasse, Germany) 24 (3) (2017)

Thomas Scattolin.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas Scattolin